¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"maximal effective dose"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • maximal growth rate
    ÃÖ´ëÁõ½Ä·ü, Ãִ뼺Àå·ü
  • maximal inspiratory level
    ÃÖ´ëµé¼û¼öÁØ, ÃÖ´ëÈí±â°ª
  • maximal midexpiratory flow rate
    ÃÖ°íÁß°£³¯¼ûÀ¯¼Ó, ÃÖ°íÁß°£È£±âÀ¯¼Ó
  • maximal stimulus
    ÃÖ´ëÀÚ±Ø
  • maximal tubular excretory capacity
    ÃÖ´ë¿ä¼¼°ü¹è¼³·®
  • maximal tubular reabsorption capacity
    ÃÖ´ë¿ä¼¼°üÀçÈí¼ö·®
  • maximal volition period
    ÃÖ´ë¼öÃà±â
  • effective alveolar ventilation
    1. À¯È¿ÆóÆ÷ȯ±â 2. À¯È¿ÆóÆ÷ȯ±â·®
  • effective capacity
    À¯È¿¿ëÀû
  • effective charge
    À¯È¿ÀüÇÏ
  • effective chlorine
    À¯È¿¿°¼Ò
  • effective circulating volume
    À¯È¿¼øÈ¯¿ëÀû
  • effective current
    À¯È¿Àü·ù
  • effective demand
    À¯È¿¼ö¿ä
  • effective filtration pressure
    À¯È¿¿©°ú¾Ð, À¯È¿°Å¸£±â¾Ð
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • maximal expiratory level
    Ãִ볯¼û¼öÁØ
  • maximal inspiratory level
    ÃÖ´ëµé¼û¼öÁØ
  • maximal stimulus
    ÃÖ´ëÀÚ±Ø
  • maximal conduction velocity
    ÃÖ´ëÀüµµ¼Óµµ
  • maximal diastolic potential
    ÃÖ´ëÀ̿ϱâÀüÀ§
  • maximal growth rate
    ÃÖ´ëÁõ½Ä·ü
  • maximal midexpiratory flow rate
    ÃÖ´ëÁß°£³¯¼ûÀ¯¼Ó
  • maximal stimulation test
    ÃÖ´ëÀڱذ˻ç
  • maximal voiding rate
    ÃÖ´ë¹è´¢À²
  • maximal volition period
    ÃÖ´ë¼öÃà±â
  • maximal voluntary ventilation
    ÃÖ´ë³ë·ÂÈ£Èí, ÃÖ´ë¼öÀÇȯ±â·®
  • effective capacity
    À¯È¿¿ë·®
  • effective charge
    À¯È¿ÀüÇÏ
  • effective chlorine
    À¯È¿¿°¼Ò
  • effective current
    À¯È¿Àü·ù
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • LD = lethal dose
    Ä¡»ç·®.
  • LD50 (50% lethal dose)
    50% Ä¡»ç·®
  • LD= lethal dose
    Ä¡»ç·®.
  • MTD=> maximum toderance dose
    ÃÖ´ë³»¿ë·®.
  • MTD=£¾maximum tolerance dose
    ÃÖ´ë³»¿ë·®.
  • MTD=ÊÝmaximum toderance dose
    ÃÖ´ë³»¿ë·®.
  • STD= standard test dose
    Ç¥ÁؽÃÇè·®.
  • absorbed dose
    Èí¼ö·®.¹æ»ç¼±Èí¼ö¼±·®(ýåâ¥àÊåÖ).
  • absorbed dose
    Èí¼ö¼±·®
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • absorbed dose rate
    Èí¼ö¼±·®À²
  • acceptable daily dose : ADD
    ÀÏÀÏÇã¿ë·®(ìéìíúÉé»Õá).
  • acceptable dose
    ¿ëÀμ±·®, ¼ö¿ë¼±·®, Çã¿ë¼±·®
  • adult dosage =a. dose
    ¼ºÀη®, ¼ºÀο뷮.
  • arbitrary dose
    ÀÓÀǿ뷮(ìòëòéÄåÖ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • minimun effective dose
    ÃÖ¼ÒÀ¯È¿¼±·®
  • cumulative dose ; cumulate dose
    ´©Àû¿ë·®.
  • cumulative dose ; cumulate dose
    ÃàÀû(¿ë)·®, ´©Àû(¿ë)·®, ´©ÀûÁ¶»ç(¿ë)·® , [¿¹¹æ] ÁýÀû¼±·®.
  • cumulative dose ; cumulate dose
    ÃàÀû(¿ë)·®, ´©Àû(¿ë)·®, ´©ÀûÁ¶»ç(¿ë)·® .[¿¹¹æ]ÁýÀû¼±·®.
  • dose rate ; dosage rate ; dose per unit time
    ¹æ»ç ÀÓº´,ÇÙÀÇ,¾à¸®¼±·®·ü, ¿ë·®.
  • optimal dose ; optimum dose
    ÃÖÀû·®, ÀûÁ¤·®(îêïáåÖ).
  • optimal dose ; optimum dose
    ¹æ»ç [¾à¸®,ÇØºÎ,¿¹¹æ]ÃÖÀû·®, ÀûÁ¤·®(ËøËøËâ).
  • optimal dose ; optimum dose
    ÃÖÀû·®, ÀûÁ¤·®(îêïáåÖ).
  • maximal afterloaded contraction
    ÃÖ´ëÈĺÎÇÏ ¼öÃà(õÌÓÞý­Ý¶ùÃâ¥õê)
  • maximal alveolar ventilation
    ÃÖ´ëÆóÆ÷ȯ±â·®.
  • maximal blood pressure
    ÃÖ´ëÇ÷¾Ð(õÌÓÞúìäâ), ÃÖ°íÇ÷¾Ð(õÌÍÔúìäâ).
  • maximal breathing capacity
    ÃÖ´ëÈ£Èí(¿ë)·®(õÌÓÞû¼ýåé»åÖ), ºÐ½ÃÃÖ´ë
  • maximal clearance
    ÃÖ´ëŬ¸®¾î·±½º, ±Ø<ÃÖ>´ëû¼Ò¿ëÀû(п<õÌ>
  • maximal diastolic potential
    ÃÖ´ëÀ̿ϱâÀü¾Ð(õÌÓÞì¬èÐÑ¢ï³äâ)
  • maximal diffusing
    ÃÖ´ëÈ®»ê(õÌÓÞüªß¤).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • median immunizing dose
    Á¤Áß ¸é¿ª·®(ïáñéØóæµÕá)
  • median infectious dose
    Á¤Áß °¨¿°·®(ïáñéÊïæøÕá)
  • median lethal dose
    Á¤Áß Ä¡»ç·®(ïáñéöÈÞÝÕá)
  • median paralysis dose
    Á¤Áß ¸¶ºñ·®(ïáñ騫ÝöÕá)
  • median tissue culture dose
    Á¤ÁßÁ¶Á÷¹è¾ç·®(ïáñéðÚòÄÛÆå×Õá)
  • median toxic dose
    Á¤Áß µ¶¼º·®(ïáñéÔ¸àõÕá)
  • minimum hemagglutinating dose
    ÃÖ¼ÒÇ÷±¸ÀÀÁý·®(õÌá³úìϹëêó¢Õá)
  • minimum hemolytic dose
    ÃÖ¼Ò¿ëÇ÷·®(õÌá³éÁúìÕá)
  • minbimum lethal dose
    ÃÖ¼ÒÄ¡»ç·®(õÌá³öÈÞÝÕá)
  • permissible dose
    Çã¿ë·®(úÉé»Õá)
  • priming dose
    ÀÏÂ÷󸮿뷮(ìéó­ô¥×âéÄÕá)
  • radiation absorbed dose
    ¹æ»ç¼± Èí¼ö·®(Û¯ÞÒàÊýåâ¥Õá)
  • radiation dose
    ¹æ»ç¼±·®(Û¯ÞÒàÊÕá)
  • threshold dose
    ¹®ÅÎ ¼±·®(àÊÕá)
  • tissue culture infectious dose
    Á¶Á÷¹è¾ç °¨¿°·® (ðÚòÄÛÆå×ÊïæøÕá)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • maintenance dose
    À¯Áö¿ë·®
  • maximum permissible dose [=MPD]
    ÃÖ´ëÇã¿ë(¼±)·®
  • median lethal dose
    50%Ä¡»ç·®, Æò±ÕÄ¡»ç·®
  • midbreast dose
    À¯¹æÁß¾ÓÁ¶»ç¼±·®
  • permissible internal dose
    ³»ºÎÇã¿ë¼±·®
  • radiation absorbed dose
    ¶óµå, ¹æ»ç¼±Èí¼ö¼±·®
  • relative dose
    ºñ±³Á¶»ç·®, »ó´ëÁ¶»ç·®
  • single dose
    ÀÏȸ·®
  • skin dose
    ÇǺμ±·®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MBC male breast cancer; maximal bladder capacity; maximal breathing capacity; metastatic breast cancer; ...
MES maintenance electrolyte solution; maximal electroshock; maximal electroshock seizures; myoelectric s...
MRE maximal resistive exercise; maximal respiratory effectiveness
PMI pain management inventory; past medical illness; patient medication instruction; perioperative myoca...
CD cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
BED biological effective dose
MED minimum effective dose
ACCESS Access to Community Care and Effective Services and Support
AERP Atrial effective refractory period
EOA Effective Orifice Area
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • effective mass
    À¯È¿ Áú·®
  • effective osmolality
    À¯È¿ »ïÅõÁú ³óµµ
  • effective ratio
    À¯È¿À²
    ¾î´À ÇѰè±îÁö´Â ¾àÁ¦ ¿ë·®°ú À¯È¿À²Àº ºñ·ÊÇÑ´Ù. ÇѰè À̻󿡼­´Â ºÎÀÛ¿ëÀÌ ³ªÅ¸³­´Ù.
  • effective tonicity
    À¯È¿ Àå·Â
  • effective weight
    À¯È¿ Áß·®
  • optimum effective temperature
    ÃÖÀû °¨°¢ ¿Âµµ
  • absorbed dose conversion factor
    Èí¼ö¼±·® º¯È¯ °è¼ö
  • air dose
    °øÁß ¼±·®, °ø±âÁß ¼±·®
    ´Ù¸¥ ¹°Ã¼¿¡ ÀÇÇÑ »ê¶õ¼±À» Á¦¿ÜÇÑ °ø±â ÁßÀÇ ¼±·®. ÀϹÝÀûÀ¸·Î ¹°Ã¼ÀÇ Ç¥¸é¿¡ À־µµ, ¶Ç´Â »ýü Á¶Á÷ ³»ÀÇ ÀÏ Á¡¿¡¼­ÀÇ ¼±·®À¸·Î¼­µµ ¸ðµç »ê¶õ¼±ÀÇ ¿µÇâÀ» ¹Þ±â ¶§¹®¿¡ °øÁß ¼±·®º¸´Ù ¸¹¾ÆÁø´Ù.
  • average dose
    Æò±Õ ¿ë·®, Æò±Õ Á¶»ç·®
  • average maintenance dose
    µð±âÅ»¸®½º Æò±Õ À¯Áö·®
  • basal dose
    ±âº» ¼±·®
  • booster dose
    Ãß°¡ Á¢Á¾·®
  • cumulative absorbed dose
    ´©Àû ¼±·®, ´©Àû Èí¼ö¼±·®
  • cumulative dose
    ÁýÀû ¼±·®, ´©Àû Á¶»ç·®, ´©Àû ¿ë·®, Ãàô ¿ë·®
  • curative dose
    ġȿ·®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
effective collision radius <radiobiology> Effective size of a particle equal to the square root of (cross-section/pi). Determines the effective range of interaction of the particle.
(09 Oct 1997)
effective conjugate The internal conjugate measured from the nearest lumbar vertebra to the symphysis, in spondylolisthesis.
Synonym: false conjugate.
(05 Mar 2000)
effective half-life <radiobiology> Time required for a radioactive substance contained in a biological system (such as a person or an animal) to reduce its radioactivity by half, as a combination result of radioactive decay and biological elimination from the system.
(09 Oct 1997)
effective osmotic pressure That part of the total osmotic pressure of a solution that governs the tendency of its solvent to pass across a boundary, usually a semipermeable membrane; it is commonly represented by the product of the total osmotic pressure of the solution and the ratio (corrected for activities) of the number of dissolved particles that do not permeate the bounding membrane to the total number of particles in the solution; equivalent in meaning to tonicity; commonly expressed in equivalent units of osmolality rather than pressure per se.
(05 Mar 2000)
effective refractory period The period during which impulses may appear but are too weak to be conducted; the longest interval between adequate stimuli, falling just short of the time necessary to allow a propagated response to be evoked in a tissue by the second stimulus; it differs from the functional refractory period in that it is a measure of stimulus interval rather than response interval of time.
(05 Mar 2000)
effective renal blood flow The amount of blood flowing to the parts of the kidney that are involved with production of constituents of urine.
(05 Mar 2000)
effective renal plasma flow <physiology> The amount of plasma flowing to the parts of the kidney that have a function in the production of constituents of urine; the clearance of substances such as iodopyracet and p-aminohippuric acid, assuming that the extraction ratio in the peritubular capillaries is 100%.
It is the amount of plasma perfusing the kidney tubules per unit time, generally measured by p-aminohippurate clearance. It should be differentiated from renal plasma flow which is approximately 10% greater than the effective renal plasma flow.
(07 Mar 2000)
effective temperature A comfort index or scale which takes into account the temperature of air, its moisture content, and movement.
(05 Mar 2000)
effective temperature index A composite index of environmental comfort which is compared after exposure to different combinations of air temperature, humidity, and movement.
(05 Mar 2000)
absorbed dose The amount of energy absorbed per unit mass of irradiated material at the target site; in radiation therapy, the former unit for absorbed dose is the rad; the current (S.I.) unit is the gray.
(05 Mar 2000)
air dose The radiation dose, expressed in roentgens, delivered at a point in free air.
Synonym: air dose.
(05 Mar 2000)
bone marrow dose The cumulative dose to the blood-forming organ from therapeutic or nuclear fallout irradiation; the presumed leukemogenic dose.
(05 Mar 2000)
booster dose A dose given at some time after an initial dose to enhance the effect, said usually of antigens for the production of antibodies.
(05 Mar 2000)
breast dose in mammography <radiology> 180 mrad / view -- mid-breast dose, guideline: less than 1 rad for 2-view exam
(12 Dec 1998)
maintenance dose In chemotherapy, systematic dosage at a level that maintains protection against exacerbation.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á